Efficacy of parenteral glutamine supplementation in adult hematopoietic stem cell transplantation patients
- Author:
Yun Kyung CHO
1
;
So Yeon HONG
;
Su Jeoung JEON
;
Hyung Wook NAMGUNG
;
Eunsook LEE
;
Euni LEE
;
Soo Mee BANG
Author Information
- Publication Type:Original Article
- Keywords: Glutamine; Hematopoietic stem cell transplantation; Parenteral nutrition
- MeSH: Adult; Glutamine; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Mortality; Mucositis; Multivariate Analysis; Nausea; Neutropenia; Odds Ratio; Parenteral Nutrition; Parenteral Nutrition, Total; Retrospective Studies; Seoul; Transplants; Vomiting
- From:Blood Research 2019;54(1):23-30
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Hematopoietic stem cell transplantation (HSCT) patients need parenteral nutrition because of nausea, vomiting, and mucositis caused by conditioning regimens. The demand for glutamine increases during the HSCT period. We evaluated the effects of glutamine-containing parenteral nutrition on the clinical outcomes of HSCT patients. METHODS: In this retrospective analysis, we reviewed HSCT patients from Seoul National University from August 2013 to July 2017. Depending on their glutamine supplementation status, 91 patients were divided into 2 groups: glutamine group (N=44) and non-glutamine group (N=47). We analyzed the rate of weight change, infection (clinically/microbiologically documented), complications (duration of mucositis and neutropenia, acute graft versus host disease), and 100-days mortality in each group. RESULTS: Regarding the clinical characteristics of the patients, there were no significant differences between the 2 groups except that there was a larger proportion of myeloablative conditioning regimen in the glutamine group (P=0.005). In the glutamine group, the average number of days of glutamine use, parenteral nutrition, and mucositis was 7.6±1.4, 14.6±9.9, and 13.3±9.5, respectively. Furthermore, multivariate analysis revealed odds ratios of 0.37 (95% CI, 0.14–0.96; P=0.042) and 0.08 (95% CI, 0.01–0.98; P=0.048) for clinically documented infection and 100-days mortality, respectively, in the glutamine group. CONCLUSION: Results showed that the glutamine group had less clinically documented infection and 100-days mortality than the non-glutamine group, but the other outcomes did not show significant differences. The extended duration of glutamine supplementation according to the period of total parenteral nutrition and mucositis should be considered.
